# 510(k) Summary - Calcium Generation 2 Assay

# Introduction

Roche Diagnostics Corporation hereby submits this $5 1 0 ( \mathbf { k } )$ to provide notification of our intent to market the Calcium Generation 2 assay. The original 510(k) summary was submitted by Kathie Goodwin on Novcmber 28, 2011. This revised version is a rcsult of the changes that occurred based on Roche's hold response.

# Submitter, name, address, contact

Roche Diagnostics 9115 Hague Road PO Box 50416 Indianapolis, IN 46250 Phone: 317-521-1942 Fax: 317-521-2324

New Primary Contact person: Lisa Klinedinst Email: lisa.klinedinst@roche.com

Date prepared: March 30, 2012

# Device name

Proprietary name: Calcium Gen. 2

Common name: CA2

Classification namc: Calcium Test System under 21 CFR 862.1145

Product code: CHW

# Device description

The Calcium Gen. 2 test system employs a photometric test method where calcium ions react with a calcium specific polyamino carboxylic acid under alkaline conditions to form a complex. This complex reacts in the second step with EDTA. The calcium concentration is directly proportional to the change in absorbance which is measured photometrically.

# 510(k) Summary - Calcium Generation 2 Assay, coninued

# Intended use

The Calcium Gen.2 assay is an in vitro diagnostics reagent system intended for quantitative determination of calcium in human serum, plasma and urine on Roche/Hitachi cobas c systems.

# Predicate device

Roche claims substantial equivalence to the currently marketed Calcium test system cleared in K921661.

The following table compares the features of the draft device with the predicate device.

Substantial equivalence   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device:Calcium (K921661)</td><td rowspan=1 colspan=1>Draft Device:Calcium Gen. 2</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro test for the quantitativedetermination of calcium inhuman serum, plasma and urineon Roche automated clinicalchemistry analyzers.</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>Serum, Heparin Plasma, and Urine</td><td rowspan=1 colspan=1>Serum, Li-Heparin Plasma andUrine</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>Roche Hitachi analyzers</td><td rowspan=1 colspan=1>cobas c 501 analyzer</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Calibrator f.a.s.</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>CalibrationFrequency</td><td rowspan=1 colspan=1>Every 3 days if the reagent bottlesare onboard the analyzer for morethan 3 days; after reagent bottlechange if the previous bottles wereonboard the analyzer for more than3 days; after reagent lot change;and as required following qualitycontrol procedures</td><td rowspan=1 colspan=1>After reagent lot change and asrequired following quality controlprocedures.</td></tr><tr><td rowspan=1 colspan=1>CalibrationMode</td><td rowspan=1 colspan=1>Two point linear</td><td rowspan=1 colspan=1>same</td></tr></table>

# 510(k) Summary - Calcium Generation 2 Assay contd

Substantial equivalence (continued)

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device:Calcium (K921661)</td><td rowspan=1 colspan=1>Draft Device:Calcium Gen. 2</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Preinorm U PlusPrecipath U Plus. Preinorm U. Precipath U</td><td rowspan=1 colspan=1>Preinorm U PlusPrecipath U Plus. Preinorm U.Precipath UPreciControl ClinChemMultilPreciControl ClinChemMulti2</td></tr><tr><td rowspan=1 colspan=1>Reagent ActiveIngredients</td><td rowspan=1 colspan=1>o-Cresolphthalein complexone, 8-hydroxyquinoline, HCI acid</td><td rowspan=1 colspan=1>5-nitro-5&#x27;-mcthyl-BAPTA</td></tr><tr><td rowspan=1 colspan=1>ReagentStability</td><td rowspan=1 colspan=1>Unopened15-25°C until expiration dateOn-board in useR1: 42 daysR2: 90 days</td><td rowspan=1 colspan=1>Unopened2-8°C until expiration dateOn-board in use42 days</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>Serum/Plasma:0.2 - 20 mg/dLUrine:0.48 - 48 mg/dL</td><td rowspan=1 colspan=1>Serum/Plasma:0.8 - 20.1 mg/dLUrine:0.8 - 30.1 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lower Limitsof Measure</td><td rowspan=1 colspan=1>Not Established</td><td rowspan=1 colspan=1>Serum/plasmaLoB: 0.4 mg/dLLoD: 0.8 mg/dLLoQ: 0.8 mg/dLUrineLoB: 0.4 mg/dLLoD: 0.8 mg/dLLoQ: 0.8 mg/dL</td></tr></table>

Continued on next page

# 510(k) Summary - Calcium Generation 2 Assay, continued

Substantial equivalence (continued)

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=4>Predicate Device:Calcium (K921661)</td><td rowspan=1 colspan=4>Draft Device:Calcium Gen. 2</td></tr><tr><td rowspan=25 colspan=1>Precision</td><td rowspan=2 colspan=1>Serum/plasma</td><td rowspan=2 colspan=2>Serum/plasmaCvMean  Repeatablity</td><td rowspan=25 colspan=1>.</td><td rowspan=1 colspan=1>Serum/plasma</td><td rowspan=1 colspan=2>lasma</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Menn</td><td rowspan=2 colspan=1>cvRepeat-abitity</td><td rowspan=2 colspan=1>CvIntermediateprecision</td></tr><tr><td rowspan=2 colspan=1>Humanserum</td><td rowspan=2 colspan=1>8.49mp/d</td><td rowspan=2 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>Humanserum 1</td><td rowspan=2 colspan=1>2.4.mp/dL</td><td rowspan=2 colspan=1>2.0%</td><td rowspan=2 colspan=1>2.5%</td></tr><tr><td rowspan=2 colspan=1>PrecltrolN</td><td rowspan=2 colspan=1>9.18mp/dL.</td><td rowspan=2 colspan=1>0.7%</td></tr><tr><td rowspan=2 colspan=1>Himanscrum 2</td><td rowspan=2 colspan=1>10.2m&amp;/dL.</td><td rowspan=2 colspan=1>0.8%</td><td rowspan=2 colspan=1>0.9%</td></tr><tr><td rowspan=2 colspan=1>PrecitrolA</td><td rowspan=2 colspan=1>13.3mg/dL</td><td rowspan=2 colspan=1>0.4%</td></tr><tr><td rowspan=2 colspan=1>Humanserum 3</td><td rowspan=2 colspan=1>17.9mg/d.</td><td rowspan=2 colspan=1>0.8%</td><td rowspan=2 colspan=1>0.9%</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=3 colspan=1>Mean</td><td rowspan=3 colspan=1>CvIntermedlateprecision</td></tr><tr><td rowspan=1 colspan=1>PrecinormU</td><td rowspan=1 colspan=1>9.0mpid</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>PrecipathU</td><td rowspan=1 colspan=1>114.mg/dl</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=1 colspan=1>HumanseTum</td><td rowspan=1 colspan=1>8.41mg/d.</td><td rowspan=1 colspan=1>1.6%</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>PrecitrolN</td><td rowspan=2 colspan=1>9.12mp/dl.</td><td rowspan=2 colspan=1>1.7%</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=3>Urine</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>PrecitrolA</td><td rowspan=1 colspan=1>13.1mgidL</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Mean</td><td rowspan=2 colspan=1>CvRepent-ablty</td><td rowspan=2 colspan=1>CvIntermediateprecision</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1></td><td rowspan=2 colspan=1>CVRepealability</td></tr><tr><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Hunianurine 1</td><td rowspan=1 colspan=1>2.3mg/dL</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1>Humanurine</td><td rowspan=1 colspan=1>14.3mp/d).</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>Humanurine 2</td><td rowspan=1 colspan=1>15.7mg/dl</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1>ControlUrine 1</td><td rowspan=1 colspan=1>6.12mg/dL</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>Humanurine 3</td><td rowspan=1 colspan=1>20.8mp/dl</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>1.1%</td></tr><tr><td rowspan=1 colspan=1>ContralUrine 2</td><td rowspan=1 colspan=1>10.8my/dL</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>Humanurine 4</td><td rowspan=1 colspan=1>24.4mg/dL</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Mean</td><td rowspan=2 colspan=1>CvIntermediatepreclsion</td><td rowspan=1 colspan=1>ConirolLevel1</td><td rowspan=1 colspan=1>7.4mg/dl</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1>ControlLevel 2</td><td rowspan=1 colspan=1>10.9mp/l</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Humanurine</td><td rowspan=1 colspan=1>14.0mg/dL</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=3 colspan=4>•</td></tr><tr><td rowspan=1 colspan=1>ControlUrine </td><td rowspan=1 colspan=1>6.04mg/dL</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=1 colspan=1>ControlUrne 2</td><td rowspan=1 colspan=1>10.7mg/dL.</td><td rowspan=1 colspan=1>1.4%</td></tr><tr><td rowspan=1 colspan=1>ExpectedValues</td><td rowspan=1 colspan=4>Serum/plasma:8.6-10.2 mg/dL24 Hour Urine:100-321 mg/24 h, corresponding to6.8-21.3 mg/dL .Reference range acc. To TietzSerum/plasma:Chidren (0-10 days): 7.6-10.4 mg/dLChildren (10 days -2 years): 9.0-11.0 mg/dLChildren (2 years-12 years): 8.8-10.8 mg/dLChildren (12-18 years): 8.4-10.2 mg/dLAdults (18-60 ycars): 8.6-10.0 mg/dLAdults (60-90 years): 8.8-10.2 mg/dLAdults (&gt;90 years): 8.2-9.6 img/dLUrine100-300 mg/24 h with normal foodintake</td><td rowspan=1 colspan=4>Reference range acc. To TietzSerum/plasma:Children (0-10 days): 7.6-10.4 mg/dLChildren (10 days -2 years): 9.0-11.0mg/dLChildren (2 years-12 years): 8.8-10.8mg/dLChildren (12-18 years): 8.4-10.2 mg/dLAdults (18-60 years): 8.6-10.0 mg/dLAdults (60-90 years): 8.8-10.2 mg/dLAdults (&gt;90 years): 8.2-9.6 mg/dLUrine100-300 mg/24 h with normalfood intake</td></tr></table>

# 510(k) Summary - Calcium Generation 2 Assay, continued Substantial equivalence (continued)

<table><tr><td>Feature</td><td>Predicate Device: Calcium (K921661) Serum/Plasma</td><td>Draft Device: Calcium Gen. 2 Serum/Plasma</td></tr><tr><td rowspan="5">Interferences</td><td rowspan="2">Icterus: no significant interference up to an I index of 60 Hemolysis: no significant interference up to and H index of 1000 Lipenia: no significant interference up to an L index of 1000 Drugs:</td><td>Same Endogenous Interferent Claims And in Addition: -The interference of intravenously administered gadolinium containing MRI (magnetic resonance imaging)</td></tr><tr><td>Optimark®) but no interference was found at the therapeutic concentration. Interference at higher concentrations was observed.</td></tr><tr><td>Drugs containing strontium salts may lead to significantly increased calcium results.</td><td>-In very rare cases gammopathy, in particular type IgM (Waldenstrom&#x27;s macroglulinemia), may cause unreliable results. Urine: Icterus:</td></tr><tr><td rowspan="2">Other: -Intravenously administered contrast media for MRI contain chelating complexes which may interfere with the determination of calcium. -A sharp decrease in calcium values was observed when gadodiamide was administered. Follow the instructions of the manufacturer with regard to the retention time of the contrast medium.</td><td>no significant interference up to a conjugated bilirubin concentration of 60 mg/dL</td></tr><tr><td>Hemolysis: no significant interference up to a hemoglobin concentration of 1000 mg/dL</td></tr><tr><td rowspan="2">unreliable results. Urine:</td><td rowspan="2">-In very rare cases gammopathy, in particular type IgM (Waldenstrom&#x27;s macroglulinemia), may cause Drugs: Drugs containing strontium salts may lead to significantly increased calcium results. therapeutic concentration, but there was interference at higher concentrations. For Optimark® interference was</td><td>Magnesium: no significant interference up to a concentration of 60 mmol/L Drugs: No interference was found at</td></tr><tr><td>therapcutic concentrations using common drug panels. Other: -The interference of intravenously administered gadolinium containing MRI (magnetic resonance imaging) Optimark). For Omniscan® no interference was observed at the</td></tr></table>

Roche Diagnostics Operations, Inc. c/o Lisa Klinedinst   
9115 Hague Road   
. P. O. Box 50416   
Indianapolis, IN 46250

Re: k113521 Trade Name: Calcium Gen.2 Regulation Number: 21 CFR $\ S 8 6 2 . 1$ 145 Regulation Name: Calcium Test System Regulatory Class: Class II Product Codes: CHW Dated: March 30, 2012 Received: April 2, 2012

Dear Ms. Klinedinst:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments; or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

![](images/834f4e99cf832810487e1a910a9ec4701fb7dd9ae1ec7657968f8d922d2843af.jpg)

Courney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Numer f 11352

Device Name: Roche/Hitachi cobas c Calcium Gen.2

Indications For Use:

The Calcium Gen.2 assay is an in vitro diagnostics reagent system intended for the quantitative determination of calcium in human serum, plasma, and urine on Roche/Hitachi cobas c systems. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease, and tetany.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/2b118d3464b48aeca22e7de7180c9e0f9b8856c318917d5de5579c76fc27e7a6.jpg)